ASRS

Speaking at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, J. Fernando Arevalo, MD, PhD, The Edmund F. and Virginia B. Ball Professor of Ophthalmology, chairman of ophthalmology at Johns Hopkins Bayview Medical Center, Wilmer Eye Institute, Johns Hopkins University, Baltimore, outlined his investigation of the anatomic and functional outcomes of pars plana vitrectomy, scleral buckle, or a combination of the 2, and suggested that the combination approach may need further consideration.

Speaking at the American Society of Retina Specialists 2022 annual meeting in New York, Carl Danzig, MD, detailed how treatment with faricimab in patients with neovascular AMD resulted in improvements in visual acuity, central subfield thickness and pigment epithelial detachments.

During a presentation at the American Society of Retina Specialists 2022 annual meeting in New York, Bobeck S. Modjtahedi, MD, presented results of a study that examined the accuracy of tools for predicting the risk of vision-threatening diabetic retinopathy.

In a presentation at the American Society of Retina Specialists, Dimitra Skondra, MD, PhD, points out that the low-to-moderate doses of metformin carried the greatest potential benefit in a retrospective case-control study.

In a presentation at the American Society of Retina Specialists 2022 annual meeting at the Jacob K. Javits Convention Center in New York, Yoshihiro Yonekawa, MD, detailed that primary scleral buckling achieved the best visual acuity, and pointed out that rhegmatogenous detachments increased with age.

In the TENAYA and LUCERNE studies, more than 60% of faricimab patients could be treated every 4 months at 2 years, an increase from 45% at year 1. Study results are being presented at the American Society of Retina Specialists 2022 annual meeting in New York.

A team of investigators form Johns Hopkins Medicine say they’ve discovered that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration may need lifelong, frequent eye injections to preserve vision or if they can be safely weaned off the treatments.

A team of investigators at the Agency for Science, Technology and Research in Singapore have developed a bio-functional thermogel, a type of synthetic polymer, to prevent retinal scarring caused by failed retinal detachment repair surgery.

The FDA has accepted the supplemental Biologics License Application of aflibercept injection for review in patients with diabetic retinopathy.

A team led by researchers from the University of Geneva has identified a molecular mechanism that causes degeneration of the eye’s photoreceptors, which can lead to blindness.

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021.

David Boyer, MD, reports on the use of pegcetacoplan to treat geographic atrophy when administered monthly or every-other-month regimens in the phase 3 DERBY and OAKS studies.

Arshad Khanani, MD, MA, reports primary study findings from the phase 3 study on the Port Delivery System with ranibizumab.

Richard B. Rosen, MD, DSc(Hon), reports on the capabilities of using clinical OCT for imaging and measuring macular surface macrophage cells during the 2021 ASRS annual meeting.

Justis P. Ehlers, MD, speaks on the findings from a higher-order OCT analysis for inflammatory signal biomarkers in the HAWK Study.

Sunir Garg, MD, reports on the risk of presumed infectious endophthalmitis following administration of anti-VEFG injections in correlation with universal masking.

Yoshihiro Yonekawa, MD, reports on the findings of an investigation looking at the prevalence of endophthalmitis following minimally invasive glaucoma surgery.

Alcon's Paul Hallen offers a look at the highlights from the 2021 ASRS annual meeting's OIS panel as well as the company's latest innovations.

Rishi Singh, MD, reports on results from the VISTA and VIVID studies analyzing the use of intravitreal aflibercept injections to treat DME.

Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.

W. Lloyd Clark, MD, presents results of the nonproliferative diabetic retinopathy-focused PANORAMA study during the 2021 ASRS annual meeting.

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Retina specialists Caesar Luo, MD, of Bay Area Retina Associates (Walnut Creek, CA) and S.K. Steven Houston III, MD, of Florida Retina Institute, share their outlooks on retina innovation in the "year of the eye" amid a global pandemic.

Dilraj Grewal, MD, speaks on his presentation "Evaluating the True 3-Year Recurrence Rate in Non-infectious Posterior Segment Uveitis Following an Injectable Fluocinolone Acetonide Insert," during ASRS 2020.

Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."

Daniel F. Kiernan, MD, FACS, speaks on the key findings and take-aways of his presentation "Dexamethasone intracameral drug-delivery suspension for inflammation associated with vitreoretinal surgery."

S.K. Steven Houston III, MD, discusses retina innovations in use in his practice, including the NGENUITY 1.4 upgrade from Alcon, and adapting to ever-changing operating room spacing and set-up in the COVID-19 environment

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.